Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025Canadian Liver Journal

Evaluation of a novel albumin platelet product (APP) fibrosis index and three non-invasive fibrosis indices in metabolic dysfunction–associated steatotic liver disease

View Full Paper
Ask AI
Bookmark
Share

Authors

ALAmy LouMEManal O. ElnenaeiELEric Liu

Discussion

Loading...

Member takes

Overview

This study finds albumin platelet product outperforms FIB-4 for fibrosis staging in diabetes patients, indicating better diagnostic potential.

Key Points

  • Albumin platelet product outperformed FIB-4 for detecting cirrhosis in patients with diabetes.
  • Both APP and FIB-4 showed similar diagnostic performance in non-diabetes patients.
  • Cirrhosis detection was notably better in the diabetes cohort for APP (AUC 0.80) compared to FIB-4 (AUC 0.76).
  • Revised FIB-4 thresholds may enhance diagnostic accuracy for MASLD patients with diabetes.

Cite This Study

Lou et al. (2025) studied this question.

synapsesocial.com/papers/68d41bfb713b0b5dfea64f30https://doi.org/10.3138/canlivj-2025-0017
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Diagnostic Performance of Fibrosis‐4 Index, Nonalcoholic Fatty Liver Disease Fibrosis Score, <scp>AST</scp>‐To‐Platelet Ratio Index, and <scp>BARD</scp> Score Among Young and Older Adults for the Diagnosis of Advanced <scp>MASLD</scp> Fibrosis: A Retrospective Cohort Study2025 · 5 citations
  2. 2Evaluation of Platelet Parameters in Relation to Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Scores among Non-alcoholic Fatty Liver Disease Patients and Healthy Controls: An Exploratory Study2025
  3. 3Correlation of Demography, Liver Function Tests, and Lipid Profile with Fibroscan Results in Patients with Nonalcoholic Fatty Liver Disease Attending a Tertiary Care Hospital in West Bengal2025
  4. 4Serum fibrosis scores as predictors of liver fibrosis and long-term outcomes in metabolic dysfunction-associated steatotic liver disease, including cirrhosis2025
  5. 5Blood Biomarkers of Fibrosis as Alternatives to FibroScan2025